ClinConnect ClinConnect Logo
Search / Trial NCT04654975

Metachronic Brain Metastases After Esophagectomy for Esophageal Cancer (METABREC)

Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Dec 3, 2020

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

ClinConnect Summary

The METABREC clinical trial is studying brain metastases, which are cancer cells that have spread to the brain, in patients who have undergone esophagectomy (surgery to remove part or all of the esophagus) for esophageal cancer. Although brain metastases are rare, they can significantly affect a patient's survival. This study aims to look back at patients treated between 2000 and 2019 to find out how often these brain metastases occur and what factors might increase the risk of developing them. Researchers want to understand whether these risks are different for patients who received chemotherapy before surgery compared to those who had surgery alone.

To be eligible for this trial, participants must have had surgical treatment for esophageal cancer within the specified time frame and have specific types of cancer, such as adenocarcinoma or squamous cell carcinoma. Unfortunately, patients with other types of cancer or those with early-stage disease will not be included. If you qualify and choose to participate, the study will involve reviewing your medical history and treatment details to gather important information about brain metastases and their potential risk factors. This research is important as it could help improve understanding and treatment options for future patients facing similar challenges.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients receiving surgical treatment for esophageal cancer between 1 januari 2000 and 31 december 2019
  • All types of neoadjuvant treatment followed by surgery, primary surgery or salvage surgery.
  • Adenocarcinoma or squamous cell carcinoma histology
  • Exclusion Criteria:
  • other histology type than adenocarcinoma or squamous cell carcinoma
  • Hypopharyngeal carcinoma extending to the esophagus (requiring total laryngo-pharyngo-esophagectomy)
  • Early esophageal carcinoma (cT IS-1a N0 M0)
  • palliative esophagectomy

About Universitaire Ziekenhuizen Ku Leuven

Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.

Locations

Houston, Texas, United States

Gent, , Belgium

Lille, , France

Rotterdam, , Netherlands

Stockholm, , Sweden

Gent, , Belgium

Lille, , France

Amsterdam, , Netherlands

Heerlen, , Netherlands

Dublin, , Ireland

Patients applied

0 patients applied

Trial Officials

Lieven P Depypere, PhD

Principal Investigator

UZ Leuven

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials